Novo Nordisk's Denecimig Timeline Slips to 2027 While Buyback and India Bet Carry the Story
Published on 10/16/2026 at 10:52 | Editorial boerse-global.de
Novo Nordisk shares changed hands at EUR 34.99 on Tuesday, a 2.6 percent gain that management declined to tie to any specific corporate development. The advance, which followed a stretch of losses, leaves the Danish drugmaker down 21 percent since the start of the year — a decline that has done little to slow its capital-return machine.
That machine is running at full tilt. Under a repurchase program launched in February with a ceiling of up to DKK 15 billion, the company had bought back 37,849,179 of its own B shares by October 9, spending DKK 10,558,876,422 in the process. The holdings now amount to 1.2 percent of total share capital. For investors watching a stock that has spent months under pressure, the steady bid offers a measure of predictability on shareholder returns even as the operating backdrop grows choppier.
A Regulatory Detour in Hemophilia
The more complicated story sits in the pipeline. The FDA has extended its review of Denecimig, an experimental treatment for hemophilia A, because of remediation work needed at a manufacturing site. The agency did not set a new decision date, though it flagged no concerns about clinical efficacy or safety. Novo Nordisk still aims for a U.S. launch in the first half of 2027, according to Reuters, and insists the holdup will not affect its financial outlook for fiscal 2026.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
India Emerges as a Growth Lever
Attention also turned this week to South Asia, where the company's India managing director projected annual growth of 15 to 20 percent for the country's GLP-1 market. An obesity pill could reach that market around mid-2027, provided regulators give the green light. With a vast population and rising rates of metabolic disease, India represents a strategic priority — and an oral therapy would open the door to patient groups that injectable formats have struggled to reach outside established Western markets.
Analyst Caution on the U.S. Franchise
Back in the United States, the mood is less buoyant. Evan Seigerman of BMO Capital cut his price target on the stock Monday to $40 from $47, keeping a Market Perform rating. His reasoning rests on a demanding year-over-year comparison and eroding U.S. market share that could weigh on Ozempic's revenue potential. The comparison problem is partly mechanical: the year-earlier quarter benefited from a positive gross-to-net effect of DKK 2 billion, making the current period a tougher benchmark.
Investors will get a clearer read on the actual trajectory — volumes, margins, and the durability of the U.S. franchise — when Novo Nordisk reports quarterly results on November 4, 2026. Until then, the buyback remains the most visible source of support for the shares.
Ad
Novo Nordisk Stock: New Analysis - 16 October
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
